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Background: Glucocorticoid (GC)-induced osteonecrosis (ON) is an important complication of medical therapy. The
exact pathomechanisms of ON has not been clearly elucidated. There is a need for a reproducible animal model
that better approximates the clinical scenario.
Methods: To determine the genetic susceptibility of rats to develop GC-induced femoral head ON, we evaluated 5
different inbred strains of rats (Spontaneous Hypertensive Rat, Wistar Kyoto, Wistar Furth, SASCO Fisher and Lewis).
Prednisone pellets (dosage of 1.82-2.56 mg/kg/day) were implanted subcutaneously for 90. After 90 days, the
femurs were resected and examined histologically and radiographically. Pathological and histological examination
was performed. Hematoxylin and eosin (H & E) staining was used to delineate the femoral head osteonecrosis
lesions as well as abnormalities of articular cartilage and growth plate.
Results: The greatest differences in H & E staining were seen in the Wistar Kyoto and Wistar Furth groups. In these
groups 4 out of 5 and 3 out of 5, respectively, steroid-induced rats revealed growth plate disruption with acellular
areas. The TUNEL apoptosis staining assay for apoptosis revealed that 4 out of 5 of Wistar Kyoto rats, 5 out of 5 of
Wistar Furth, 2 out of 4 of surviving Lewis and 2 out of 2 of the surviving spontaneous hypertensive rats had
apoptotic osteocytes in trabeculae, whereas none of the Fisher rats showed apoptotic osteocytes.
Conclusions: We postulate that Wistar Kyoto, Wistar Furth and spontaneous hypertensive rats may be strains of
rats more susceptible to develop ON of the femoral head while Fisher rats were the most resistant.
Background
Glucocorticoids (GCs) are widely prescribed in cases of
rheumatoid arthritis, asthma, systemic lupus erythema-
tosus, cancer, organ transplantation and many other
medical conditions. The therapeutic use of GCs has
been accompanied by marked side effects, especially
with the long-term usage of this drug. The adverse
effect of GCs on bone has been recognized for more
than 60 years [1-3]. The bone effect is characterized by
decreased bone formation and in situ death of isolated
segments of bone which may be associated with osteo-
necrosis (ON) particularly important clinically for the
femoral head. ON in the femoral head gradually pro-
gresses to fracture of the subchondral bone, collapse of
the surface and hip arthritis. Although ON has been
linked to a variety of conditions, GC usage remains the
predisposing factor most commonly associated with the
development of non-traumatic ON. There is consider-
able interest in identifying which patients are at highest
risk for ON, with the long-term goal of modifying regi-
mens to decrease the risk of adverse effects of therapy.
Despite the strong association of GC administration
with ON, the role of potential underlying risk factors
such as hyperlipidemia, thrombophilia, and hyperfibrino-
lysis in the circulatory system remain unclear [2,4]. It
has been clearly established that among patients receiv-
ing a specific dose of GC, only an unpredictable subset
will develop ON. This underscores the existence of indi-
vidual variability in the action of GCs and the potential
presence of additional mechanisms and/or risk factors
such as a genetic predisposition. On the other hand,
studying the clinical pathology of ON in the early dis-
ease stage (before radiographic findings) is extremely
difficult in human subjects. Thus, animal experiments
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order. Having a suitable animal model would allow for
the systemic evaluation of host-related (ie. genetic var-
iations) as well as acquired (ie. treatment-related) risk
factors. GC-induced ON has been induced in rabbit
models [5-8], bipedal animals (e.g., chickens, emus)
[9,10] and recently, in BALB/cJ mice [11]. GC-induced
ON has been described in mature Japonese white rab-
bits (Kbs-JW) [5,8] but the genome of rabbit has only
been incompletely sequenced, thus limiting the useful-
ness of that model for the identification of genes
affecting the risk of developing ON. The biped models
are difficult to interpret in the context of bone healing
as we do not have a full grasp of avian bone healing.
Although a mouse model of GC-induced ON is inter-
esting, the very small diameter of the femoral head of
mice limits the application of numerous experiments
and monitoring techniques. It is currently impossible
to read an MRI or radiograph from a mouse with the
goal of differentiating a normal hip from a hip with
ON changes. A rat model would allow easier radio-
graphic interpretation, allow facile surgical interven-
tions, allow existing small animal facilities to be used
as well as be in an animal where the genetics of heal-
ing is much better understood. To date, there has been
no rat model of GC-induced ON unless it has been
combined with a surgical procedure [12] or in combi-
nation with immune responses stimuli [13]. These
blood interruption studies do not faithfully model the
more prevalent non-traumatic ON. In this study, our
goal was to establish a rat model of GC-induced ON
by screening different strains of rats in order to
uncover those whose constitutive phenotype might
predispose to the development of ON.
Methods
Maintenance and experimental animals
In this pilot study, female retired breeder (aged 6-8
months) Fisher, Lewis, Spontaneous Hypertensive, Wis-
tar Kyoto, and Wistar Furth rats (6 of each strain) were
obtained from Charles River Laboratories (Pointe-Claire,
QC, Canada). The rats were tagged and housed in plas-
tic cages (2 animals per cage) under standard laboratory
conditions with a 12-hour dark/12-hour light cycle, a
constant temperature of 20°C, and humidity of 48%.
Food and water were provided ad libitum with a stan-
dard rodent diet. The weight of the rats were followed
before and after the implant of a prednisone pellet for
the first 4 consecutive days, then every week until the
end of the experiment. All experiments were conducted
under an animal protocol (Protocol No. 4935) approved
by the McGill Animal Care Department, Montreal,
Canada.
Glucocorticoid administration
Slow-release prednisone pellets (Innovative Research of
America, Sarasota, Florid, USA) were implanted subcu-
taneously in 5 inbred rats composing each group
(Fisher, Lewis, Spontaneous Hypertensive, Wistar Kyoto
and Wistar Furth). Each pellet was implanted under-
neath the skin on the lateral side of the neck by surgi-
cally making an incision and developing a pocket about
2 cm beyond the incision site. The pellet was placed in
the pocket and the incision was sutured. Based on the
manufacturer’s instructions the pellet releases a constant
dose of the drug subcutaneously. The average dose
release from the pellet was equivalent to 1.82-2.56 mg/
kg/day (mean: 2.26, SD: 0.19) for a period of 90 days.
This dosage is an equivalent dosage to humans that
commonly causes ON changes. Thus, each group had 5
GC-induced rats along with 1 control rat in each group
not treated with prednisone (the control rat did not
receive a placebo pellet).
Histological Examination
The rats were sacrificed with an overdose of ketamine/
xylazine following 90 days of the experiment. Tissue
samples were obtained from the femoral head. Bone
samples were fixed in 10% neutral buffered formalin
overnight, then decalcified in 4% ethylenediamine tetraa-
cetic acid (pH 7.2) (Sigma-Aldrich, St. Louis, MO, USA).
The specimens were processed routinely and embedded
in paraffin. Tissue sections were cut parasagitally with a
rotary microtome to obtain 4 to 5 microns thickness,
stained with hematoxylin and eosin (H & E) and evalu-
ated by light microscopy.
Tissue samples were analyzed in a blinded fashion by
an experienced bone pathologist (AN). GC-induced ON
was diagnosed based on bone and growth plate changes.
The histological findings of an established ON were
defined as dead trabeculae exhibiting empty lacunae
with or without appositional bone formation [14]. Occa-
sional empty lacunae possibly created by sectioning
through the edge of a lacunae was not considered as a
sign for ON. The growth plate changes were considered
as thinning, discontinuity pattern and disruption of
articular cartilage alignment or growth plate alignment.
Tissue sections were also examined according to the
criteria of Arlet et al. namely presence of degeneration,
necrosis, and disappearance of marrow cells as well as
the nuclear disappearance and hypochromasia of trabe-
cular osteocytes as early signs of ON [15]. Early signs of
ON was also considered when apoptosis occurred in the
osteocytes and osteoblasts. Positivity for apoptosis was
defined by the authors as 2 to 3 apoptotic osteocytes
and/or osteoblasts considered as one plus, between 3 to
6 as two plus and more than 6 as three plus recognized
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were performed in triplicate.
Measurement of apoptosis in undecalcified bone section
We used terminal deoxynucleotidyl transferase dUTP
nick end labeling (TUNEL assay) to detect DNA frag-
mentation by labeling the terminal end of nucleic acids.
In Situ Cell Death Detection Kit was obtained from
Roche (Germany). TUNEL assay on paraffin-embedded
tissue sections was performed as recommended by the
manufacturer. Briefly, after deparaffinization and per-
meabilization of the tissue sections with proteinase K,
the slides were incubated with the TUNEL reaction mix-
ture containing TUNEL-Enzyme solution and TUNEL-
Label solution for 1 hour at 37°C inside a humidified
chamber. After washing steps, samples were analyzed
under a fluorescence microscope (in a drop of 1× PBS).
The excitation wavelength ranged between 450-500 nm
whereas the detection wavelength ranged between 515-
565 nm (green). DNase I-treated tissue section was used
a sap o s i t i v ec o n t r o l .N e g a t i v ec o n t r o l sf o rt h es t u d y
constituted of sample slides processed using the same
procedure but only treated with TUNEL-Label solution.
Faxitron X-ray
Based on the histological results Faxitron x-ray analysis
was performed initially on a group of Wistar Kyoto rats
(5 rats, 10 femoral head samples) (Model MX-20). Pre-
vious work has shown that radiographic changes were a
late finding in steroid induced ON in the rat model
used. We performed the Faxitron radiographs on this
group to ensure there were no significant changes
despite changes on histology.
Statistical Analysis
Comparison between groups was made with Fisher’s
Exact test. Significant differences were considered at P
values less than 0.05.
Results
We observed a high mortality rate in some strains of
rats after prednisone implantation. Interestingly, the
Lewis and spontaneous hypertensive strains of rats
seemed to be at highest risk (mortality rate was 1 out of
5 and 3 out of 5, respectively and no mortality for other
strains). There was an overall mortality rate of 16%
among the steroid-treated rats in our pilot study related
to the development of GC-induced hyperglycemia in
these “older” rats (a two to three times fold increase
compare to control rats).
Growth plate changes were observed in Wistar Kyoto
and Wistar Furth rats (Figure 1). In these groups 4 out
of 5 and 3 out of 5 of steroid-induced rats revealed
growth plate disruption with acellular areas, respectively.
Osteocyte necrosis and empty lacunae were not detected
in any samples. TUNEL assay for apoptosis revealed that
4 / 5o fW i s t a rK y o t o ,5 / 5o fW i s t a rF u r t h ,2 / 4o fL e w i s
and 2/2 Spontaneous Hypertensive rats had apoptotic
osteocytes in trabeculae, whereas none of the Fisher rats
showed apoptotic osteocytes (Table 1, Figure 2). In the
Lewis group, apoptosis of osteocytes and osteoblasts
without any degeneration of the growth plate was
observed. Overall, the most apoptosis rate was in spon-
taneous hypertensive rats (+++) and then Wistar Furth
(++) and Wistar Kyoto (++). The apoptosis level in
Lewis and Fisher rats was (+) and zero, respectively.
Bone marrow and chondrocyte apoptotic cells were seen
in all strains of rats, even the control rats as expected.
There were no signs of inflammation and necrosis, such
as hyperemia, round cell infiltration, or lipid cyst forma-
tion. Plain x-rays obtained from Faxitron analysis did
not reveal any significant anomaly in the initial group of
Wystar Kyoto rats. Often diminished bone density was
noticed in rats exposed to glucocorticoid. The radio-
graphs were not performed in the other groups because
of the lack of changes. If there had been changes in the
initial group the other strains would have been tested.
This finding also confirmed that plain x-rays are not a
suitable method to diagnose early stages of ON in rats.
Discussion
A strain dependant genetic predisposition may be
responsible for the high mortality rate observed in some
strains of rats after prednisone implantation. Recogni-
tion of this complication of hyperglycemia has been
reported in young rats [16] and seems to be important
when choosing a model for ON. It would make these
two strains less desirable for this usage.
The rat growth plate is present throughout the life-
cycle. This may confound the findings of ON for late
stage ON in that reparative changes will overcome the
initiating stimulus- particularly in traumatic vascular
interruption studies. For this GC study, the high dosages
of steroid given will result in early ongoing changes in
the rat femoral head despite reparative processes from
the growth plate. Because of this a rodent model is pos-
sible for early ON.
Growth plate disruption was observed particularly in
Wistar Kyoto and Wister Furth strains. This was
observed in early stages of the disease- before radio-
graphic change was evident. Other studies using blood
supply interruption (ischemic model) have also shown
growth plate changes. Trueta and Amato used animal
models and showed that the blood supply to the carti-
lage of the growth plate of the femoral head originates
from the epiphyseal vessels [17], while the metaphysis is
supplied by metaphyseal vessels and nutrient arteries
coming from the medullary cavity. Mechanical damage
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growth plate and, eventually, a physeal bridge [18]. It is
possible that thrombosis in the metaphyseal arteries
reported in ON of the femoral head could cause injury
and disruption of the growth plate with areas lacking
normal cells. Sato et al. have also shown that apoptosis
tended to occur in early stages of ON. In their rat study
of ischemic ON, apoptosis occurred 12 hours after the
mechanical insult, whereas no evidence of apoptosis
remained after 96 hours, at which time only empty lacu-
nae were detected [19]. They postulated that the
mechanism of cell death involved in ischemic ON was
apoptosis as indicated by DNA fragmentation and the
presence of apoptosis bodies in osteocytes [11,20]. In
the present study, apoptosis of chrondrocytes were not
only detected in GC-induced rats but also in control
rats indicating that apoptosis of chondrocytes is not
characteristic of ON but probably more indicative of
normal bone turnover if observed in small amounts.
Other studies have shown that apoptosis of osteocytes
and osteoblasts is an important process in developing
ON, especially in the early stages of ON [21]. Kabata
and his colleagues demonstrated extensive osteocyte
apoptosis in a rabbit model of GC-induced ON [22].
Shibahara et al. also reported the presence of a large
number of apoptotic osteocytes around necrotic areas
[23]. In the present study, we observed that apoptosis
occurred at the level of osteocytes, osteoblasts, and bone
marrow cells in the early stages of GC-induced ON
lesions in three strains of inbred rats: Wistar Kyoto,
Figure 1 Photomicrographs showing histological findings in steroid-induced rat models. H & E staining in a control rat (A) versus
glucocorticoid-induced rats of all groups (B: Lewis, C: Fisher, D: Wistar Kyoto, E: Wistar Furth and F: Spontaneous Hypertensive rats). Normal
growth plate and its discontinuity pattern are shown by arrows and arrowheads, respectively. Magnification ×200.
Table 1 Apoptosis of the femoral head of GC-induced
inbred rats from 5 different strains (WKY: Wistar Kyoto,
WF: Wistar Furth, SHR: Spontaneous Hypertensive rat,).
Strain Bone Marrow Osteocyte Chondrocyte
Lewis 4/4 2/4* 4/4
Fischer 5/5 0/5* 5/5
WKY 5/5 4/5* 5/5
WF 5/5 5/5* 5/5
SHR 2/2 2/2* 2/2
*Fisher’s Exact Test (P value = 0.0039).
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sis has been shown to play an important role in main-
taining haematopoietic stem cells (HSC) homeostasis
in in vivo. Thus, apoptosis of the HSC could occur as
part of the normal physiology in bone marrow cells
[24]. Previously, it has been shown that apoptosis
could happen in bone marrow of control rats [25].
Apoptosis could result from a direct effect of GCs on
the bone cells or could be secondary to the dysfunc-
tion/activation of other cells such as the femoral head
endothelial cells [26]. Fisher rats were resistant to the
development of osteocyte apoptosis in response to GC
induction. Given the observed inter-strain variability of
susceptibility to the development of GC-induced ON
lesions, it is probable that genetic factors are involved
in ON developing in response to GCs. To date differ-
ent genetic variations and mutations accounting for
ON have been reported. A 4G/4G mutation of the
plasminogen activator inhibitor-1 gene [27], a G– >A
transition in exon 50 (p.G1170S) of collagen type II
(COL2A1) [28] and a promoter polymorphisms of the
vascular endothelial growth factor (VEGF) gene [29]
were reported to be correlated with the occurrence of
ON of the femoral head. Identifying the genetic factors
may prove relevant to the human disorder and facili-
tate the identification of individuals at increased risk of
developing ON.
Conclusions
Based on these findings, Wistar Kyoto, Wistar Furth and
Spontaneously Hypertensive rats were the most suscep-
tible strains to develop GC-induced ON of the femoral
head. The Spontaneously Hypertensive rats had a high
mortality rate that is unacceptable for a study model.
Fisher rats were resistant to the development of ON at
the GC dosage used, based on the absence of osteocyte
apoptosis in early stages of the disease process.
Although several other investigations have reported ON
in rats following the administration of GCs, our rat
model has shown early stage disease regardless of addi-
tional adjuvants such as surgery [12] or immune
response stimuli [13,30] as previously reported. It is pos-
sible that extended exposure to GCs could establish the
histological criteria of the later stages of ON.
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